HK1097194A1 - Liposomal formulations of anthracycline agents and cytidine analogs - Google Patents

Liposomal formulations of anthracycline agents and cytidine analogs

Info

Publication number
HK1097194A1
HK1097194A1 HK07104820.1A HK07104820A HK1097194A1 HK 1097194 A1 HK1097194 A1 HK 1097194A1 HK 07104820 A HK07104820 A HK 07104820A HK 1097194 A1 HK1097194 A1 HK 1097194A1
Authority
HK
Hong Kong
Prior art keywords
liposomal formulations
liposomes
cytarabine
daunorubicin
cytidine analogs
Prior art date
Application number
HK07104820.1A
Other languages
English (en)
Inventor
Lawrence Mayer
Sharon Johnstone
Troy Harasym
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Publication of HK1097194A1 publication Critical patent/HK1097194A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
HK07104820.1A 2004-04-22 2007-05-04 Liposomal formulations of anthracycline agents and cytidine analogs HK1097194A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56521004P 2004-04-22 2004-04-22
PCT/CA2005/000625 WO2005102359A1 (fr) 2004-04-22 2005-04-22 Formulations a vecteur intracellulaires pour anthracycliniques et analogues cytidiniques

Publications (1)

Publication Number Publication Date
HK1097194A1 true HK1097194A1 (en) 2007-06-22

Family

ID=35196733

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07104820.1A HK1097194A1 (en) 2004-04-22 2007-05-04 Liposomal formulations of anthracycline agents and cytidine analogs

Country Status (12)

Country Link
US (2) US8022279B2 (fr)
EP (2) EP2407169A1 (fr)
JP (1) JP4972545B2 (fr)
AU (1) AU2005235455B2 (fr)
CA (1) CA2564542C (fr)
CY (2) CY1113012T1 (fr)
ES (1) ES2388064T3 (fr)
HK (1) HK1097194A1 (fr)
IL (1) IL178779A (fr)
NL (1) NL300960I2 (fr)
PT (1) PT1744764E (fr)
WO (1) WO2005102359A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2581133A1 (fr) * 2004-09-20 2006-03-30 British Columbia Cancer Agency Gemcitabine libre ou encapsulee dans des liposomes seule ou en association avec de l'idarubicine libre ou encapsulee dans des liposomes
EP2279726A3 (fr) * 2005-05-26 2012-06-20 Biorest Ltd. Compositions et méthodes d'utilisation desdites compositions dans l'administration d'agents dans un organe cible protégé par une barrière sanguine
DK3300601T3 (da) * 2007-02-16 2022-03-21 Rotalec Ip Holdings Llc Faste lægemiddelforhold til behandling af hæmatopoietiske kræftformer og proliferative lidelser
EP2257310A2 (fr) * 2008-02-26 2010-12-08 Nerviano Medical Sciences S.r.l. Combinaison antitumorale comprenant un dérivé de morpholinyle anthracycline et des agents de déméthylation
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
BR112014009305B1 (pt) 2011-10-21 2023-01-24 Celator Pharmaceuticals Inc. Composição lipossomal de fase gel liofilizada
EA031986B1 (ru) 2012-04-04 2019-03-29 Галозим, Инк. Способ и комбинация для лечения солидной раковой опухоли и набор, содержащий комбинацию
HUE053247T2 (hu) 2012-05-09 2021-06-28 Cantex Pharmaceuticals Inc Mieloszuppresszió kezelése
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
AU2016256979B2 (en) 2015-05-04 2021-01-28 Versantis AG Method for preparing transmembrane pH-gradient vesicles
WO2017078009A1 (fr) * 2015-11-02 2017-05-11 富士フイルム株式会社 Composition liposomale et son procédé de production
CN115414376A (zh) 2015-11-11 2022-12-02 塞拉特药物股份有限公司 选择白血病对象的治疗方案的分析和方法
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
CN110869029A (zh) * 2017-07-09 2020-03-06 拜欧赛特有限公司 组合癌症治疗
WO2019222435A1 (fr) 2018-05-16 2019-11-21 Halozyme, Inc. Procédés de sélection de sujets pour une polythérapie anticancéreuse avec un ph20 soluble conjugué à un polymère
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
CN113181117B (zh) * 2021-03-22 2022-08-26 沈阳药科大学 一种紫草素和蒽环类化疗药共载脂质体及其制备方法和应用
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (fr) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5059421A (en) * 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
GB9613182D0 (en) 1996-06-24 1996-08-28 Nycomed Imaging As Method
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
ES2186484B1 (es) 2000-10-10 2004-07-01 Lipotec, S.A. Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos.
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
IL161187A0 (en) * 2001-10-03 2004-08-31 Celator Technologies Inc Liposome compositions containing metal ions and therapeutic agents
CA2383259A1 (fr) * 2002-04-23 2003-10-23 Celator Technologies Inc. Composes synergiques
US20040265368A1 (en) * 2003-04-02 2004-12-30 Lawrence Mayer Combination compositions of camptothecins and fluoropyrimidines
US20060165744A1 (en) * 2003-05-22 2006-07-27 Neopharm, Inc Combination liposomal formulations

Also Published As

Publication number Publication date
PT1744764E (pt) 2012-08-30
CA2564542C (fr) 2012-11-27
IL178779A0 (en) 2007-05-15
EP1744764B1 (fr) 2012-05-30
CA2564542A1 (fr) 2005-11-03
EP1744764A1 (fr) 2007-01-24
US8022279B2 (en) 2011-09-20
EP2407169A1 (fr) 2012-01-18
JP4972545B2 (ja) 2012-07-11
CY1113012T1 (el) 2016-04-13
EP1744764A4 (fr) 2009-04-01
US20070286897A1 (en) 2007-12-13
AU2005235455B2 (en) 2011-01-20
NL300960I2 (nl) 2019-05-22
WO2005102359A1 (fr) 2005-11-03
WO2005102359A8 (fr) 2005-12-15
US20120009252A1 (en) 2012-01-12
CY2018033I1 (el) 2019-07-10
CY2018033I2 (el) 2019-07-10
AU2005235455A1 (en) 2005-11-03
ES2388064T3 (es) 2012-10-08
JP2007533670A (ja) 2007-11-22
IL178779A (en) 2013-12-31
US8431806B2 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
HK1097194A1 (en) Liposomal formulations of anthracycline agents and cytidine analogs
CY1119865T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον
WO2007056264A3 (fr) Methodes de traitement anticancereux avec des formulations d'un compose de platine a base de lipides d'une haute activite administrees par voie intraperitoneale
EP1320369A4 (fr) Methode analgesique
MY132073A (en) Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
WO2005105141A3 (fr) Conjugues meningococciques combines presentant une proteine porteuse commune
SG153830A1 (en) Galenic formulations of organic compounds
ATE399171T1 (de) Camptothecinanaloge und deren zubereitungsmethoden
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
WO2005023294A3 (fr) Systeme de liberation de medicament en deux phase
WO2003000194A3 (fr) Derives bicycliques de pyridine et de pyrimidine utiles en tant qu'agents anticancereux
PL310344A1 (en) Lyposome containing therapeutic preparations for administration by injection
WO2007056263A3 (fr) Methodes de traitement anticancereux avec des formulations d'un compose de platine a base de lipides d'une haute activite administrees par voie intraveineuse
WO2008095144A3 (fr) Libération contrôlée d'agents actifs dans la peau
EP1177791A3 (fr) Utilisation d'inhibiteur de la glycogen phosphorylase pour inhiber la croissance de tumeurs
BR0013642A (pt) Análogos de nucleosìdeo de pirrolo[2,3-d]pirimidina
WO2006095363A3 (fr) Preparations injectables de diclofenac et sels acceptables sur le plan pharmaceutique de celui-ci
WO2009052491A3 (fr) Formulations de fénoldopam et dérivés de promédicaments
WO2004058140A3 (fr) Liposomes non-peg a longue circulation
WO2004110497A3 (fr) Methode de traitement de tumeurs resistantes aux antibiotiques
WO2005055933A3 (fr) Nouveau traitement et compositions
WO2002024661A3 (fr) Derives benzimidazolone n,n'-disubstitues presentant une affinite pour les recepteurs de la serotonine et de la dopamine
PT1292303E (pt) Formulacao farmaceutica estavel compreendendo modificacao de torsemida ii
CA2474703A1 (fr) Agent therapeutique contre le glaucome contenant de la bunazosine et desprostaglanines
ES2170649B1 (es) Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.